Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | ANPEP | P15144 | 2/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14715049 | 0.89 | PPARG (0.51) | HRH3PPARGANPEPMMP1GAA | |
| SCHEMBL14714845 | 0.86 | HRH3 (0.45) | HRH3PPARGANPEPMMP1MMP2 | |
| SCHEMBL14714735 | 0.86 | PPARG (0.49) | HRH3PPARGANPEPMCHR1 | |
| SCHEMBL14714921 | 0.85 | HRH3 (0.56) | HRH3PPARGANPEPMCHR1MMP2 | |
| SCHEMBL14715425 | 0.84 | PPARG (0.50) | HRH3PPARGANPEPMMP1MMP2 | |
| SCHEMBL14715327 | 0.84 | ALDH1A1 (0.50) | HRH3PPARGANPEPMCHR1 | |
| SCHEMBL14714987 | 0.83 | HRH3 (0.45) | HRH3PPARGANPEPMCHR1MMP1 | |
| SCHEMBL14715090 | 0.83 | PPARG (0.47) | HRH3PPARGANPEPMCHR1MMP1 | |
| SCHEMBL14714981 | 0.82 | ANPEP (0.49) | HRH3PPARGANPEPMMP1GAA | |
| SCHEMBL14714895 | 0.82 | PPARG (0.46) | HRH3PPARGANPEPMMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9499477-B2 | Hydroxamic acid derivative | TOYAMA CHEMICAL CO., LTD. (JP) | 2016-11-22 | — | — | US | disclosed |
| US-9499477-B2 | Hydroxamic acid derivative | TOYAMA CHEMICAL CO., LTD. (JP) | 2016-11-22 | — | — | US | disclosed |
| US-20150225335-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2015-08-13 | — | — | US | disclosed |
| US-20150225335-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2015-08-13 | — | — | US | disclosed |
| US-9073821-B2 | Hydroxamic acid derivative | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2015-07-07 | — | — | US | disclosed |
| US-9073821-B2 | Hydroxamic acid derivative | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2015-07-07 | — | — | US | disclosed |
| US-20130072677-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-03-21 | — | — | US | disclosed |
| US-20130072677-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-03-21 | — | — | US | disclosed |
| EP-2562155-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2013-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225335-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE | LCT, AGXT, HDAC9 | HRH3 1334/4885PPARG 972/4885ANPEP 774/4885 |
| US-20130072677-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE | LCT, AGXT, HDAC9 | HRH3 1334/4885PPARG 972/4885ANPEP 774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.